Cargando…

Prospective changes of cardiac iron and function by MR in pediatric thalassemia major patients treated with different chelators or not chelated

Detalles Bibliográficos
Autores principales:	Meloni, Antonella, Pitrolo, Lorella, Neri, Mari Giovanna, Restaino, Gennaro, Tudisca, Chiara, Preziosi, Paolo, Keilberg, Petra, Armari, Sabrina, Positano, Vincenzo, Pepe, Alessia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4328678/ http://dx.doi.org/10.1186/1532-429X-17-S1-P365

Ejemplares similares

Different patterns of myocardial iron overload by multislice T2* Cardiovascular MR as markers of risk for cardiac dysfunction in thalassemia major
por: Meloni, Antonella, et al.
Publicado: (2011)

Right ventricular wall motion abnormalities n Thalassemia Major patients
por: Meloni, Antonella, et al.
Publicado: (2014)

Association between serum ferritin and liver iron concentration with cardiac iron in pediatric thalassemia major patients
por: Meloni, Antonella, et al.
Publicado: (2016)

Regional myocardial contractility in Thalassemia Major by magnetic resonance tagging
por: Meloni, Antonella, et al.
Publicado: (2014)

Diabetes mellitus and cardiac complications in thalassemia major patients
por: Pepe, Alessia, et al.
Publicado: (2012)

Different patterns of myocardial iron overload by T2* Cardiovascular MR as markers of risk for cardiac complication in thalassemia major
por: Meloni, Antonella, et al.
Publicado: (2012)

A prospective MRI study of left ventricular iron and function in non-trasfusion-dependent thalassemia intermedia patients treated with desferrioxamine
por: Meloni, Antonella, et al.
Publicado: (2015)

Reference ranges for biventricular volumes and ejection fraction and for left ventricular mass in adult thalassemia intermedia patients without myocardial iron overload
por: Meloni, Antonella, et al.
Publicado: (2013)

Left ventricular global function index and left ventricular mass volume ratio by CMR: relation with heart failure in Thalassemia major patients
por: Meloni, Antonella, et al.
Publicado: (2015)

Prospective changes of pancreatic iron in patients with thalassemia major and association with chelation therapy
por: Meloni, Antonella, et al.
Publicado: (2022)

Iron Chelation Therapy in Thalassemia Syndromes
por: Cianciulli, Paolo
Publicado: (2009)

Thalassemia Intermedia: Chelator or Not?
por: Lee, Yen-Chien, et al.
Publicado: (2022)

Myocardial iron overload in sickle/thalassemia patients of Italian origin
por: Meloni, Antonella, et al.
Publicado: (2013)

P1457: MOTION ABNORMALITIES IN THE LEFT VENTRICLE OF THALASSEMIA INTERMEDIA PATIENTS
por: Meloni, Antonella, et al.
Publicado: (2023)

Prospective comparison on cardiac iron by MR in thalassemia major patients treated with combination deferipron-desferrioxamine versus deferipron and desferrioxamine in monoterapy
por: Pepe, Alessia, et al.
Publicado: (2011)

CMR survey in Thalassemia Intermedia patients
por: Meloni, Antonella, et al.
Publicado: (2014)

Heart T2* for prediction of cardiac complications in well-treated thalassemia major patients
por: Pepe, Alessia, et al.
Publicado: (2012)

An automatic method for myocardial T2* curve fitting in thalassemia patients with severe iron overload
por: Meloni, Antonella, et al.
Publicado: (2013)

Cardiac Function and Iron Chelation in Thalassemia Major and Intermedia: a Review of the Underlying Pathophysiology and Approach to Chelation Management
por: Aessopos, Athanasios, et al.
Publicado: (2009)

MRI prospective survey on cardiac and hepatic iron in transfusion-dependent thalassemia intermedia patients treated with desferrioxamine, deferiprone and deferasirox
por: Meloni, Antonella, et al.
Publicado: (2015)

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia
por: Bou-Fakhredin, Rayan, et al.
Publicado: (2017)

Promoting Adherence to Iron Chelation Treatment in Beta-Thalassemia Patients
por: Eziefula, Chinea, et al.
Publicado: (2022)

Changes of cardiac iron and function during pregnancy in trasfusion-dependent thalassemia patients
por: Meloni, Antonella, et al.
Publicado: (2016)

Prospective changes of cardiac iron and function in low and intermediate-1 risk mds patients
por: Pepe, Alessia, et al.
Publicado: (2015)

Beliefs about chelation among thalassemia patients
por: Trachtenberg, Felicia L, et al.
Publicado: (2012)

Long-Term Effects of Iron Chelating Agents on Ocular Function in Patients with Thalassemia Major
por: Nuzzi, Raffaele, et al.
Publicado: (2021)

Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation
por: Motta, Irene, et al.
Publicado: (2020)

Prognostic CMR parameters for heart failure and arrhythmias in large cohort of well treated thalssemia major patients
por: Meloni, Antonella, et al.
Publicado: (2014)

Iron chelating properties of Eltrombopag: Investigating its role in thalassemia-induced osteoporosis
por: Punzo, Francesca, et al.
Publicado: (2018)

Barriers to adherence to iron chelation therapy among adolescent with transfusion dependent thalassemia
por: Mohamed, Rafaa, et al.
Publicado: (2022)

Successful chelation in beta-thalassemia major in the 21(st) century
por: Fragodimitri, Christina, et al.
Publicado: (2023)

Significant improvement of survival by T2* CMR in thalassemia major
por: Meloni, Antonella, et al.
Publicado: (2016)

Left Ventricular Volumes, Mass and Function normalized to the body surface area, age and gender from CMR in a large cohort of well-treated Thalassemia Major patients without myocardial iron overload
por: Meloni, Antonella, et al.
Publicado: (2011)

Pancreatic fatty replacement as risk marker for altered glucose metabolism and cardiac iron and complications in thalassemia major
por: Meloni, Antonella, et al.
Publicado: (2023)

On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure
por: Pennell, DJ, et al.
Publicado: (2011)

Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion
por: Veríssimo, Monica Pinheiro de Almeida, et al.
Publicado: (2013)

Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions
por: Saliba, Antoine N, et al.
Publicado: (2015)

Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia
por: Susanah, Susi, et al.
Publicado: (2020)

A systematic review of adherence to iron chelation therapy among children and adolescents with thalassemia
por: Reddy, Paavani S., et al.
Publicado: (2022)

Therapeutic potential of silymarin as a natural iron‐chelating agent in β‐thalassemia intermedia
por: Reisi, Nahid, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3oq38olgmqernvuvp8mj9chbv9